

DAFTAR PUSTAKA

- Aoki, M., Aoki, H., *et al.* 2016. Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential. *Hindawi Publishing Corporation*. doi: 10.1155/2016/8606878.
- Banerjee, K., Resat, H. and Gene, T. 2017. Constitutive activation of STAT3 in breast cancer cells: A review. *HHS Public Access* 138(11), pp. 2570–2578. doi: 10.1002/ijc.29923.Constitutive.
- Bertoli, G., Cava, C. and Castiglioni, I. 2015. Micrnas: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. *Theranostics* 5(10). pp. 1122–1143. doi: 10.7150/thno.11543.
- Bhatia, A. and Kumar, Y. 2014. Cellular and molecular mechanisms in cancer immune escape : a comprehensive review. *Expert Rev. CLin. Immunol.* 10 (1). pp. 41–62.
- Boldrini, L., Giordano, M., *et al.* 2017. Role of microRNA - 33a in regulating the expression of PD - 1 in lung adenocarcinoma. *Cancer Cell International*. BioMed Central, pp. 1–7. doi: 10.1186/s12935-017-0474-y.
- Das, K., Chan, X. B., *et al.* 2016. NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer?. doi: 10.1136/esmooopen-2015-000009.
- Eichmuller, S. B., Osen, W., *et al.* 2017. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape. *JNCI J. Natl. Cancer Inst.* 109(10). pp. 1–14. doi: 10.1093/jnci/djx034.
- Fadjari, H. 2012. Pendekatan Diagnosis Benjolan di Payudara. *Cermin Dunia Kedokteran*, 39(4), pp. 308–310.
- Fang, G., Liu, J., *et al.* 2017. MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression. *Int. J. Mol. Sci.* 18 (1208). doi: 10.3390/ijms18061208.
- Formenti, S. C., Lee, P., *et al.* 2018. Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer. doi: 10.1158/10780432.CCR-17-3322.
- Foye, C., Yan, I. K., *et al.* 2017. Comparison of miRNA quantitation by Nanostring in serum and plasma samples. *PLoS ONE* 12 (12). pp. 1–13.
- Franceschetti, T., Dole, N. S. *et al.* 2014. Pathway Analysis of MicroRNA Expression Profile during Murine Osteoclastogenesis. *PLoS ONE* 9(9), pp. 1–13. doi: 10.1371/journal.pone.0107262.

- Goh, J. N., Loo, S. Y., et al. 2016. microRNAs in breast cancer : regulatory roles governing the hallmarks of cancer. *Biol. Rev.* 91, pp. 409–428. doi: 10.1111/brv.12176.
- Guo, L., Zhang, Y., et al. 2016. MicroRNAs , TGF- β signaling , and the inflammatory microenvironment in cancer. *Tumor Biol.* 37: pp. 115–125. doi: 10.1007/s13277-015-4374-2.
- Hamam, R., Ali, A. M., et al. 2016. microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. *Nature Publishing Group*. Nature Publishing Group, (May): 1–8. doi: 10.1038/srep25997.
- Haque, S. and Morris, J. C. 2017. Transforming Growth Factor-beta : A Therapeutic Target for Cancer. *Human Vaccines & Immunotherapeutics* 5515(June), pp. 0–22.
- Hou, P., Kang, Y. and Luo, J. 2018. Hypoxia-mediated miR-212-3p downregulation enhances progression of intrahepatic cholangiocarcinoma through upregulation of. 4047. doi: 10.1080/15384047.2018.1456608.
- How, C. and How, C. 2013. Characterization of Altered MicroRNA Expression in Cervical Cancer. Thesis. Graduate Department of Medical Biophysics University of Toronto.
- Hu, F., Meng, Q., et al. 2013. Biochimica et Biophysica Acta BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer. *BBA - Molecular Basis of Disease*. Elsevier B.V., 1832(12): 2379–2390.
- Kolbert, C. P., Feddersen, R. M. et al. 2013. Multi-Platform Analysis of MicroRNA Expression Measurements in RNA from Fresh Frozen and FFPE Tissues. *PLoS ONE* 8(1). doi: 10.1371/journal.pone.0052517.
- Lee, S., Lee, H., et al. 2016. Epigenetic silencing of miR-19a-3p by cold atmospheric plasma contributes to proliferation inhibition of the MCF-7 breast cancer cell', *Nature Publishing Group*. Nature Publishing Group, (July), pp. 1–10. doi: 10.1038/srep30005.
- Leichter, A. L., Purchell, R. V., et al. 2018. Multi-platform microRNA profiling of hepatoblastoma patients using formalin fixed paraffin embedded archival samples. *GigaScience* 4(54) doi: 10.1186/s13742-015-0099-9.
- Li, S. et al. 2015. Mir-192 suppresses apoptosis and promotes proliferation in esophageal squamous cell carcinoma by targeting Bim. 8(7), pp. 8048–8056.
- Li, T. et al. 2018. *PT SC. Pathology -- Research and Practice*. Elsevier GmbH. doi: 10.1016/j.prp.2018.02.017.
- Macfarlane, L. and Murphy, P. R. 2010. MicroRNA : Biogenesis , Function and

Role in Cancer: 537–561.

- Morris, J. C., Tan, A. R., et al. 2014. Phase I Study of GC1008 (Fresolimumab): A Human Anti- Transforming Growth Factor-Beta (TGF β) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. *PLoS ONE* 9(3). doi: 10.1371/journal.pone.0090353.
- Nassar, A., Visscher, D. W., et al. 2015. Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study', *Breast Cancer Research and Treatment*, 153(2), pp. 397–405. doi: 10.1007/s10549-0153535-8.
- Neuzillet, C., Tijeras-Raballand, A., et al. 2015. Pharmacology & Therapeutics Targeting the TGF β pathway for cancer therapy. *Pharmacology & Therapeutics* 147, pp. 22–31. doi: 10.1016/j.pharmthera.2014.11.001.
- Pinatel, E. M. *et al.* 2014. miR-223 Is a Coordinator of Breast Cancer Progression as Revealed by Bioinformatics Predictions. 9(1). doi: 10.1371/journal.pone.0084859.
- Preparation, S., Protocols, H. and N, F. A. 2000. miRNA Expression Assay User Manual. Nanostring.
- Rohan, T., Ye, K., et al. 2018. MicroRNA expression in benign breast tissue and risk of subsequent invasive breast cancer. *PLoS ONE* 13 (2). pp. 1–13.
- Shi, Y. *et al.* 2015. miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REG γ ', *Cancer Letters*. Elsevier Ireland Ltd, 358(1), pp. 27–36. doi: 10.1016/j.canlet.2014.12.014.
- Song, C. *et al.* 2015. miR-200c inhibits breast cancer proliferation by targeting KRAS. 6(33).
- Tahiri, A., Leivonen, S., et al. 2014. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors', *Carcinogenesis*, 35(1). pp. 76–85. doi: 10.1093/carcin/bgt333.
- Vlachos, I. S. *et al.* 2018. DIANA-miRPath v3 . 0 : deciphering microRNA function with experimental support. 43(May 2015), pp. 460–466. doi: 10.1093/nar/gkv403.
- Voutsadakis, I. A. 2016. Immune Blockade Inhibition in Breast Cancer. *Anticancer Research*, 36(11). pp. 5607–5622. doi: 10.21873/anticancer.11145.
- Wang, G. *et al.* 2010. Signal Transducers and Activators of Transcription-1 (STAT1) Regulates microRNA Transcription in Interferon γ -Stimulated HeLa Cells. 5(7), pp. 1–8. doi: 10.1371/journal.pone.0011794.
- Wang, M., Zhang, C., et al. 2017. Mechanism of immune evasion in breast

- cancer. *OncoTargets and Therapy* 10. pp. 1561–1573. doi: 10.2147/OTT.S126424.
- Wei, F. *et al.* 2015. Diverse functions of miR-373 in cancer: 1–8. doi: 10.1186/s12967-015-0523-z.
- Wu, J., Du, K. and Lu, X. 2015. Elevated expressions of serum miR-15a , miR-16 , and miR-17-5p are associated with acute ischemic stroke. 8(11): 21071–21079.
- Yang, X., Kandil, D., et al. 2014. Fibroepithelial tumors of the breast: Pathologic and immunohistochemical features and molecular mechanisms. *Archives of Pathology and Laboratory Medicine* 138(1): 25–36. doi: 10.5858/arpa.2012-0443-RA.
- Zaeem, M., Janji, B., et al. 2017. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. *Oncoimmunol.* 6(1): 1–7. doi: 10.1080/2162402X.2016.1263412.
- Zhao, J. *et al.* 2015. MicroRNA - 7 : a promising new target in cancer therapy', *Cancer Cell International*. BioMed Central: 1–8. doi: 10.1186/s12935-015-0259-0.
- Zhang, J. *et al.* 2015. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. *Med. Oncol.* 32 (3): 86.